アクセス数 : ?
ダウンロード数 : ?
ID 112369
タイトル別表記
Non-clinical studies for oncology drug development
著者
Hayakawa, Yoshihiro Pharmaceuticals and Medical Devices Agency|University of Toyama
Kawada, Manabu Pharmaceuticals and Medical Devices Agency|Microbial Chemistry Research Foundation
Nishikawa, Hiroyoshi Pharmaceuticals and Medical Devices Agency|National Cancer Center
Ochiya, Takahiro Pharmaceuticals and Medical Devices Agency|National Cancer Center
Saya, Hideyuki Pharmaceuticals and Medical Devices Agency|Keio University
Seimiya, Hiroyuki Pharmaceuticals and Medical Devices Agency|Japanese Foundation for Cancer Research
Yao, Ryoji Pharmaceuticals and Medical Devices Agency|Japanese Foundation for Cancer Research
Hayashi, Masahiro Pharmaceuticals and Medical Devices Agency|Toranomon Hospital
Kai, Chieko Pharmaceuticals and Medical Devices Agency|The University of Tokyo
Matsuda, Akira Pharmaceuticals and Medical Devices Agency|Hokkaido University
Naoe, Tomoki Pharmaceuticals and Medical Devices Agency|Nagoya Medical Center
Ohtsu, Atsushi Pharmaceuticals and Medical Devices Agency|National Cancer Center
岡崎, 拓 Pharmaceuticals and Medical Devices Agency|Tokushima University KAKEN研究者をさがす
Saji, Hideo Pharmaceuticals and Medical Devices Agency|Kyoto University
佐田, 政隆 Pharmaceuticals and Medical Devices Agency|Tokushima University 徳島大学 教育研究者総覧 KAKEN研究者をさがす
Sugimura, Haruhiko Pharmaceuticals and Medical Devices Agency|Hamamatsu University School of Medicine
Sugiyama, Yuichi Pharmaceuticals and Medical Devices Agency|RIKEN
Toi, Masakazu Pharmaceuticals and Medical Devices Agency|Kyoto University
Irimura, Tatsuro Pharmaceuticals and Medical Devices Agency|Juntendo University
キーワード
Animal model
cancer
drug development
oncology drug
regulatory science
資料タイプ
学術雑誌論文
抄録
Non-clinical studies are necessary at each stage of the development of oncology drugs. Many experimental cancer models have been developed to investigate carcinogenesis, cancer progression, metastasis, and other aspects in cancer biology and these models turned out to be useful in the efficacy evaluation and the safety prediction of oncology drugs. While the diversity and the degree of engagement in genetic changes in the initiation of cancer cell growth and progression are widely accepted, it has become increasingly clear that the roles of host cells, tissue microenvironment, and the immune system also play important roles in cancer. Therefore, the methods used to develop oncology drugs should continuously be revised based on the advances in our understanding of cancer. In this review, we extensively summarize the effective use of those models, their advantages and disadvantages, ranges to be evaluated and limitations of the models currently used for the development and for the evaluation of oncology drugs.
掲載誌名
Cancer Science
ISSN
13497006
出版者
Japanese Cancer Association
107
2
開始ページ
189
終了ページ
202
発行日
2016-02-26
権利情報
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
先端酵素学研究所
医学系